EP2005958A4 - EXTERNAL PHARMACEUTICAL COMPOSITION - Google Patents
EXTERNAL PHARMACEUTICAL COMPOSITIONInfo
- Publication number
- EP2005958A4 EP2005958A4 EP06811056A EP06811056A EP2005958A4 EP 2005958 A4 EP2005958 A4 EP 2005958A4 EP 06811056 A EP06811056 A EP 06811056A EP 06811056 A EP06811056 A EP 06811056A EP 2005958 A4 EP2005958 A4 EP 2005958A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- pharmaceutical composition
- external pharmaceutical
- external
- composition
- pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL06811056T PL2005958T3 (en) | 2006-03-08 | 2006-10-02 | External pharmaceutical composition |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006062079 | 2006-03-08 | ||
JP2006215871 | 2006-08-08 | ||
PCT/JP2006/319708 WO2007102242A1 (en) | 2006-03-08 | 2006-10-02 | External pharmaceutical composition |
Publications (3)
Publication Number | Publication Date |
---|---|
EP2005958A1 EP2005958A1 (en) | 2008-12-24 |
EP2005958A4 true EP2005958A4 (en) | 2010-09-15 |
EP2005958B1 EP2005958B1 (en) | 2013-04-17 |
Family
ID=38474687
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP06811056.8A Active EP2005958B1 (en) | 2006-03-08 | 2006-10-02 | External pharmaceutical composition |
Country Status (16)
Country | Link |
---|---|
US (3) | US8349882B2 (en) |
EP (1) | EP2005958B1 (en) |
JP (1) | JP5160409B2 (en) |
KR (1) | KR101343291B1 (en) |
AU (1) | AU2006339842B2 (en) |
BR (1) | BRPI0621446C1 (en) |
CA (1) | CA2645070C (en) |
ES (1) | ES2421613T3 (en) |
IL (1) | IL193894A (en) |
MX (1) | MX2008011435A (en) |
NZ (1) | NZ571819A (en) |
PL (1) | PL2005958T3 (en) |
RU (1) | RU2423128C2 (en) |
TW (1) | TWI389686B (en) |
WO (1) | WO2007102242A1 (en) |
ZA (1) | ZA200808531B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104662017A (en) * | 2012-09-14 | 2015-05-27 | 宝丽制药股份有限公司 | Amide derivative and use of the same as stability index of a luliconazole pharmaceutical formulation |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2645070C (en) | 2006-03-08 | 2014-02-04 | Nihon Nohyaku Co., Ltd. | Pharmaceutical composition for external use |
US8058303B2 (en) | 2006-03-08 | 2011-11-15 | Nihon Nohyaku Co, Ltd | Pharmaceutical composition for external use |
BRPI0621386B8 (en) | 2006-03-08 | 2021-07-13 | Nihon Nihyaku Co Ltd | pharmaceutical composition for external use |
WO2009031642A1 (en) * | 2007-09-05 | 2009-03-12 | Pola Pharma Inc. | Pharmaceutical composition |
JP5345937B2 (en) | 2007-09-05 | 2013-11-20 | 株式会社ポーラファルマ | Antifungal composition |
ES2591030T3 (en) * | 2007-09-05 | 2016-11-24 | Pola Pharma Inc. | Antifungal Pharmaceutical Composition |
CA2752557A1 (en) | 2009-02-13 | 2010-08-19 | Topica Pharmaceuticals, Inc. | Anti-fungal formulation |
US10130610B2 (en) | 2009-04-09 | 2018-11-20 | Pola Pharma Inc. | Antimycotic pharmaceutical composition |
CN102387786B (en) * | 2009-04-09 | 2015-09-09 | 宝丽制药股份有限公司 | Antifungal medicine composition |
US8952044B2 (en) | 2009-08-25 | 2015-02-10 | Pola Pharma Inc. | Antimycotic pharmaceutical composition |
US8962669B2 (en) | 2010-06-11 | 2015-02-24 | Pola Pharma Inc. | Antimycotic pharmaceutical composition |
JP5980700B2 (en) * | 2012-03-19 | 2016-08-31 | 株式会社ポーラファルマ | Resin container filled with antifungal pharmaceutical composition |
RU2621615C2 (en) * | 2012-09-14 | 2017-06-06 | Пола Фарма Инк. | Pharmaceutical composition comprising luliconazole |
RU2622644C2 (en) | 2012-09-14 | 2017-06-19 | Пола Фарма Инк. | Crystalline substance and pharmaceutical preparation containing it |
US9068958B1 (en) | 2012-09-14 | 2015-06-30 | Pola Pharma Inc. | Use of surface free energy for differential evaluation of crystal, crystal evaluated on basis of surface free energy as index, and pharmaceutical composition prepared by containing the crystal |
WO2014041708A1 (en) | 2012-09-14 | 2014-03-20 | Pola Pharma Inc. | Crystal having crystal habits and pharmaceutical composition obtained by processing the crystal |
JP6067399B2 (en) * | 2013-02-08 | 2017-01-25 | 株式会社ポーラファルマ | Pharmaceutical composition |
JP5662495B2 (en) * | 2013-02-08 | 2015-01-28 | 株式会社ポーラファルマ | Pharmaceutical composition in solubilizer form |
JP5730340B2 (en) * | 2013-02-08 | 2015-06-10 | 株式会社ポーラファルマ | Reservoir type pharmaceutical composition |
JP5589110B1 (en) | 2013-03-08 | 2014-09-10 | 株式会社ポーラファルマ | Crystal having crystal habit and pharmaceutical composition containing the crystal as an active ingredient |
JP6503626B2 (en) * | 2013-03-28 | 2019-04-24 | 大正製薬株式会社 | Pharmaceutical composition |
JP6503627B2 (en) * | 2013-03-28 | 2019-04-24 | 大正製薬株式会社 | Pharmaceutical liquid composition |
JP2016518306A (en) * | 2013-05-17 | 2016-06-23 | 株式会社ポーラファルマ | Pharmaceutical composition for diseases with Aspergillus, Candida, etc. as pathogens |
JP5680161B1 (en) | 2013-09-06 | 2015-03-04 | 株式会社ポーラファルマ | Crystal having crystal habit and pharmaceutical composition containing the crystal as an active ingredient |
JP5587488B1 (en) | 2013-12-12 | 2014-09-10 | 株式会社ポーラファルマ | Evaluation method and index substance of preparation containing luliconazole |
US9480746B2 (en) | 2014-04-21 | 2016-11-01 | Pola Pharma Inc. | Resin container filled with antifungal pharmaceutical composition |
JP6110839B2 (en) * | 2014-12-04 | 2017-04-05 | 株式会社ポーラファルマ | Pharmaceutical composition in solubilizer form |
TR201714882A2 (en) | 2017-10-03 | 2019-04-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Topical pharmaceutical compositions of luliconazole |
US10898470B1 (en) | 2019-08-13 | 2021-01-26 | Sato Pharmaceutical Co., Ltd. | Pharmaceutical composition containing antifungal agent as active ingredient |
CN112773762B (en) * | 2019-11-08 | 2023-04-18 | 威智医药股份有限公司 | External-use medicine composition and preparation method and application thereof |
RU2738595C1 (en) * | 2020-03-17 | 2020-12-14 | Марина Михайловна Бурмина | Therapeutic and cosmetic composition |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1537868A1 (en) * | 2002-06-18 | 2005-06-08 | Pola Chemical Industries, Inc. | Antifungal medicinal compositions |
WO2005123136A1 (en) * | 2004-06-15 | 2005-12-29 | Hisamitsu Pharmaceutical Co., Inc. | Antiinflammatory and analgesic preparation for external use |
Family Cites Families (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4267169A (en) * | 1978-07-22 | 1981-05-12 | Toko Yakuhin Kogyo Kabushiki Kaisha | Novel preparation of clotrimazole |
JPS5815909A (en) | 1981-07-22 | 1983-01-29 | Toko Yakuhin Kogyo Kk | Antimycotic agent for external use |
US4636520A (en) * | 1984-07-16 | 1987-01-13 | Fujisawa Pharmaceutical Co., Ltd. | Antifungal composition employing pyrrolnitrin in combination with an imidazole compound |
JPH0236572B2 (en) | 1984-11-13 | 1990-08-17 | Hokuriku Pharmaceutical | SUTEROIDOO177MONOESUTERUGANJUKURIIMUZAI |
JPS6293227A (en) | 1985-10-19 | 1987-04-28 | Nippon Nohyaku Co Ltd | Antimycotic agent |
US4764381A (en) * | 1985-12-06 | 1988-08-16 | Key Pharmaceuticals, Inc. | Percutaneous penetration enhancer of oleic acid and 2-ethyl-1, 3-hexanediol |
JPH0774144B2 (en) | 1986-03-12 | 1995-08-09 | 久光製薬株式会社 | Skin composition containing urea |
US5686489A (en) | 1986-12-23 | 1997-11-11 | Tristrata Technology, Inc. | Alpha hydroxyacid esters for skin aging |
JPH01242525A (en) | 1988-03-25 | 1989-09-27 | Nippon Nohyaku Co Ltd | Antifungal topical agent |
JPH01246219A (en) | 1988-03-25 | 1989-10-02 | Nippon Nohyaku Co Ltd | Antifungal topical cream composition |
JP3030780B2 (en) | 1988-12-29 | 2000-04-10 | 日本農薬株式会社 | Optically active ketene dithioacetal derivative and method for producing the same |
JPH02264723A (en) | 1989-04-06 | 1990-10-29 | Taisho Pharmaceut Co Ltd | antifungal agent |
KR920700655A (en) | 1989-05-26 | 1992-08-10 | 찰스 엠. 브럭 | Injectable Clarithromycin Composition |
IL97012A0 (en) | 1990-01-30 | 1992-03-29 | Gist Brocades Nv | Topical preparations for treating human nails |
US5340836A (en) * | 1991-02-19 | 1994-08-23 | Mark S. Reinhard | Composition and method for treatment of vaginal yeast infections |
FR2673537B1 (en) * | 1991-03-08 | 1993-06-11 | Oreal | USE OF HYDROPHILIC PENETRATION AGENTS IN DERMATOLOGICAL COMPOSITIONS FOR THE TREATMENT OF ONYCHOMYCOSES, AND CORRESPONDING COMPOSITIONS. |
JP2555555B2 (en) | 1991-07-03 | 1996-11-20 | 武田薬品工業株式会社 | Antifungal topical formulation |
JPH06199701A (en) | 1992-12-29 | 1994-07-19 | Lion Corp | Anti-inflammatory analgesic agent for external use |
WO1995001160A1 (en) * | 1993-07-01 | 1995-01-12 | Yamanouchi Europe B.V. | Stable topical retinoid compositions |
JPH06211651A (en) | 1993-01-12 | 1994-08-02 | Hisamitsu Pharmaceut Co Inc | Composition for treating nail trichophytosis |
JPH0774144A (en) | 1993-06-29 | 1995-03-17 | Sony Corp | Cleaning method for plasma apparatus |
DE4337945A1 (en) * | 1993-11-06 | 1995-05-11 | Labtec Gmbh | Plasters for the treatment of nail mycoses |
JP2860748B2 (en) * | 1993-12-24 | 1999-02-24 | エスエス製薬株式会社 | Stable hydrocortisone butyrate-containing cream |
JP3803393B2 (en) | 1994-01-12 | 2006-08-02 | 久光製薬株式会社 | Nail ringworm treatment composition |
JP3629283B2 (en) | 1994-02-15 | 2005-03-16 | ポーラ化成工業株式会社 | Skin preparation |
JP3081766B2 (en) | 1994-05-06 | 2000-08-28 | 東興薬品工業株式会社 | Keratin storage type antifungal external composition |
GB9420355D0 (en) * | 1994-10-10 | 1994-11-23 | Univ Nottingham | Preparation of protein microspheres, films and coatings |
WO1996011710A1 (en) | 1994-10-13 | 1996-04-25 | Hisamitsu Pharmaceutical Co., Inc. | External preparation for nail ringworm |
SE9502244D0 (en) * | 1995-06-20 | 1995-06-20 | Bioglan Ab | A composition and a process for the preparation thereof |
EP0839035B1 (en) * | 1995-07-08 | 2002-10-02 | Nihon Nohyaku Co., Ltd. | Antifungal agent, compound therefor, process for producing the same |
US6008256A (en) * | 1995-08-28 | 1999-12-28 | Showa Yakuhin Kako Co., Ltd. | Composition for local anesthesia |
US5993787A (en) * | 1996-09-13 | 1999-11-30 | Johnson & Johnson Consumer Products, Inc. | Composition base for topical therapeutic and cosmetic preparations |
JP4253047B2 (en) | 1996-09-27 | 2009-04-08 | 杏林製薬株式会社 | Film-forming antifungal composition |
JP4227677B2 (en) | 1996-12-10 | 2009-02-18 | 杏林製薬株式会社 | Film-forming antifungal composition |
JPH10226686A (en) | 1996-12-10 | 1998-08-25 | Nippon Nohyaku Co Ltd | (R)-(E)-(4-substituted phenyl-1,3-dithiolan-2-ylidene) -1-imidazoleacetonitrile derivatives which are optically active substances, antifungal agents and methods for producing them |
AU7936198A (en) * | 1998-07-01 | 2000-01-24 | Lead Chemical Co., Ltd. | Ketotifen preparation for percutaneous absorption |
US5962536A (en) * | 1998-07-31 | 1999-10-05 | Komer; Gene | Injectable propofol formulations |
US6740326B1 (en) * | 1998-09-10 | 2004-05-25 | Bioequal Ag | Topical nail care compositions |
US20040208906A1 (en) * | 1999-07-12 | 2004-10-21 | Daiichi Suntory Pharma Co., Ltd. | Pharmaceutical composition for topical administration |
JP2001064206A (en) * | 1999-08-30 | 2001-03-13 | Isp Japan Kk | Percutaneous absorption-promoting composition |
US7074392B1 (en) | 2000-03-27 | 2006-07-11 | Taro Pharmaceutical Industries Limited | Controllled delivery system of antifungal and keratolytic agents for local treatment of fungal infections |
US6428654B1 (en) * | 2000-04-05 | 2002-08-06 | Hercules Incorporated | Fungicidal method |
JP2002114680A (en) | 2000-07-31 | 2002-04-16 | Nippon Nohyaku Co Ltd | Antifungal agent |
JP2002193755A (en) | 2000-12-28 | 2002-07-10 | Sansho Seiyaku Co Ltd | Anti-dandruff and Kayumi cosmetics for hair and hair wash |
JP2002284702A (en) | 2001-01-19 | 2002-10-03 | Teika Seiyaku Kk | Topical antifungal preparations |
KR100423666B1 (en) | 2001-02-07 | 2004-03-18 | 보령제약 주식회사 | Composition of Antifungal Topical preparations |
US6585963B1 (en) | 2001-02-15 | 2003-07-01 | Watson Pharmaceuticals, Inc. | Nail compositions and methods of administering same |
US20030017207A1 (en) * | 2001-05-01 | 2003-01-23 | Lin Shun Y. | Compositions and methods for treating vulvovaginitis and vaginosis |
JP2002363070A (en) | 2001-06-06 | 2002-12-18 | Yuutoku Yakuhin Kogyo Kk | Transdermal patch preparation |
KR100640039B1 (en) | 2001-09-04 | 2006-10-31 | 트롬스도르프 게엠베하 운트 코. 카게 알츠나이미텔 | Plaster, containing sertaconazole, for the treatment of dysfunction and diseases of the nail |
JP2003252798A (en) | 2002-02-28 | 2003-09-10 | Shiseido Co Ltd | Antibacterial gel preparation |
US6846837B2 (en) * | 2002-06-21 | 2005-01-25 | Howard I. Maibach | Topical administration of basic antifungal compositions to treat fungal infections of the nails |
JP4387639B2 (en) | 2002-07-16 | 2009-12-16 | 久光製薬株式会社 | Transdermal absorption preparation |
CA2492976C (en) | 2002-09-05 | 2011-11-01 | Galderma Research & Development, S.N.C. | Solution for ungual and peri-ungual application |
US20060140984A1 (en) * | 2002-10-25 | 2006-06-29 | Foamix Ltd. | Cosmetic and pharmaceutical foam |
DK1635770T3 (en) | 2003-03-21 | 2009-08-03 | Nexmed Holdings Inc | Antifungal nail polish and method of application |
JP4931128B2 (en) | 2003-04-10 | 2012-05-16 | ニューロジェシックス, インコーポレイテッド | Methods and compositions for administration of TRPV1 agonists |
US20070099932A1 (en) * | 2003-06-25 | 2007-05-03 | Toshihiro Shirouzu | External preparation for athlete's foot treatment |
JP4431369B2 (en) | 2003-11-21 | 2010-03-10 | 久光製薬株式会社 | Antifungal aerosol topical preparation |
JP4429035B2 (en) | 2004-02-27 | 2010-03-10 | 久光製薬株式会社 | Cream preparation for external use with enhanced keratin retention |
JP3783104B2 (en) | 2004-03-31 | 2006-06-07 | 小林製薬株式会社 | Antifungal composition for external use |
JP4690672B2 (en) | 2004-07-20 | 2011-06-01 | 岩城製薬株式会社 | Emulsion skin external preparation |
JP3800232B2 (en) | 2004-09-30 | 2006-07-26 | 小林製薬株式会社 | Antifungal composition for external use |
JP2006306734A (en) | 2005-04-26 | 2006-11-09 | Tsumura & Co | Urea formulation external preparation |
JP5290582B2 (en) | 2005-12-28 | 2013-09-18 | 帝國製薬株式会社 | Pharmaceutical composition for nail |
CA2645070C (en) | 2006-03-08 | 2014-02-04 | Nihon Nohyaku Co., Ltd. | Pharmaceutical composition for external use |
BRPI0621386B8 (en) | 2006-03-08 | 2021-07-13 | Nihon Nihyaku Co Ltd | pharmaceutical composition for external use |
US8058303B2 (en) * | 2006-03-08 | 2011-11-15 | Nihon Nohyaku Co, Ltd | Pharmaceutical composition for external use |
WO2008075207A2 (en) | 2006-04-04 | 2008-06-26 | Foamix Ltd. | Anti-infection augmentation foamable compositions and kit and uses thereof |
WO2009031642A1 (en) * | 2007-09-05 | 2009-03-12 | Pola Pharma Inc. | Pharmaceutical composition |
JP5345937B2 (en) * | 2007-09-05 | 2013-11-20 | 株式会社ポーラファルマ | Antifungal composition |
ES2591030T3 (en) * | 2007-09-05 | 2016-11-24 | Pola Pharma Inc. | Antifungal Pharmaceutical Composition |
CA2752557A1 (en) * | 2009-02-13 | 2010-08-19 | Topica Pharmaceuticals, Inc. | Anti-fungal formulation |
US10130610B2 (en) * | 2009-04-09 | 2018-11-20 | Pola Pharma Inc. | Antimycotic pharmaceutical composition |
CN102387786B (en) * | 2009-04-09 | 2015-09-09 | 宝丽制药股份有限公司 | Antifungal medicine composition |
-
2006
- 2006-10-02 CA CA2645070A patent/CA2645070C/en active Active
- 2006-10-02 MX MX2008011435A patent/MX2008011435A/en active IP Right Grant
- 2006-10-02 PL PL06811056T patent/PL2005958T3/en unknown
- 2006-10-02 US US12/281,967 patent/US8349882B2/en active Active
- 2006-10-02 RU RU2008139905/15A patent/RU2423128C2/en active
- 2006-10-02 EP EP06811056.8A patent/EP2005958B1/en active Active
- 2006-10-02 BR BRPI0621446A patent/BRPI0621446C1/en active IP Right Grant
- 2006-10-02 ES ES06811056T patent/ES2421613T3/en active Active
- 2006-10-02 AU AU2006339842A patent/AU2006339842B2/en active Active
- 2006-10-02 WO PCT/JP2006/319708 patent/WO2007102242A1/en active Application Filing
- 2006-10-02 NZ NZ571819A patent/NZ571819A/en unknown
- 2006-10-02 JP JP2008503739A patent/JP5160409B2/en active Active
-
2007
- 2007-03-08 TW TW096107973A patent/TWI389686B/en active
-
2008
- 2008-09-04 IL IL193894A patent/IL193894A/en active IP Right Grant
- 2008-10-07 ZA ZA2008/08531A patent/ZA200808531B/en unknown
- 2008-10-07 KR KR1020087024539A patent/KR101343291B1/en active IP Right Grant
-
2012
- 2012-12-04 US US13/693,987 patent/US20130096187A1/en not_active Abandoned
-
2016
- 2016-11-03 US US15/342,525 patent/US20170071911A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1537868A1 (en) * | 2002-06-18 | 2005-06-08 | Pola Chemical Industries, Inc. | Antifungal medicinal compositions |
WO2005123136A1 (en) * | 2004-06-15 | 2005-12-29 | Hisamitsu Pharmaceutical Co., Inc. | Antiinflammatory and analgesic preparation for external use |
Non-Patent Citations (1)
Title |
---|
See also references of WO2007102242A1 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104662017A (en) * | 2012-09-14 | 2015-05-27 | 宝丽制药股份有限公司 | Amide derivative and use of the same as stability index of a luliconazole pharmaceutical formulation |
Also Published As
Publication number | Publication date |
---|---|
IL193894A0 (en) | 2009-09-22 |
US8349882B2 (en) | 2013-01-08 |
IL193894A (en) | 2015-03-31 |
KR101343291B1 (en) | 2013-12-18 |
BRPI0621446B1 (en) | 2020-10-13 |
AU2006339842A1 (en) | 2007-09-13 |
US20130096187A1 (en) | 2013-04-18 |
US20090137651A1 (en) | 2009-05-28 |
BRPI0621446A2 (en) | 2011-12-13 |
MX2008011435A (en) | 2009-02-03 |
JP5160409B2 (en) | 2013-03-13 |
EP2005958B1 (en) | 2013-04-17 |
NZ571819A (en) | 2011-04-29 |
ZA200808531B (en) | 2009-12-30 |
RU2423128C2 (en) | 2011-07-10 |
EP2005958A1 (en) | 2008-12-24 |
TWI389686B (en) | 2013-03-21 |
AU2006339842B2 (en) | 2012-06-07 |
US20170071911A1 (en) | 2017-03-16 |
BRPI0621446C1 (en) | 2021-05-25 |
CA2645070C (en) | 2014-02-04 |
KR20080111044A (en) | 2008-12-22 |
RU2008139905A (en) | 2010-04-20 |
BRPI0621446B8 (en) | 2021-02-02 |
PL2005958T3 (en) | 2013-11-29 |
CA2645070A1 (en) | 2007-09-13 |
TW200744588A (en) | 2007-12-16 |
WO2007102242A1 (en) | 2007-09-13 |
JPWO2007102242A1 (en) | 2009-07-23 |
ES2421613T3 (en) | 2013-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2025337A4 (en) | EXTERNAL PHARMACEUTICAL COMPOSITION | |
EP2005959A4 (en) | EXTERNAL PHARMACEUTICAL COMPOSITION | |
EP2005958A4 (en) | EXTERNAL PHARMACEUTICAL COMPOSITION | |
LTC2140867I2 (en) | Pharmaceutical composition | |
EP2191826A4 (en) | PHARMACEUTICAL COMPOSITION | |
BRPI0715712A2 (en) | PHARMACEUTICAL COMPOSITION | |
BRPI0719393A2 (en) | Pharmaceutical Composition | |
DK2041139T3 (en) | Pharmaceutical compounds | |
RU2398586C3 (en) | PHARMACEUTICAL COMPOSITION | |
BRPI0721651A2 (en) | PHARMACEUTICAL COMPOSITION | |
DK2073795T3 (en) | Abuse-safe drug formulation | |
EP1982718A4 (en) | ANTICANCER PHARMACEUTICAL COMPOSITION | |
EP2191828A4 (en) | ANTIFUNGAL PHARMACEUTICAL COMPOSITION | |
BRPI0714539A2 (en) | "PHARMACEUTICAL FORMS" | |
BRPI0720234A2 (en) | PHARMACEUTICAL COMPOSITION | |
BRPI0716445A2 (en) | pharmaceutical composition | |
BRPI0810928A2 (en) | "pharmaceutical composition" | |
BRPI0820381A2 (en) | Pharmaceutical Formulations | |
RU2493831C3 (en) | PHARMACEUTICAL COMPOSITIONS | |
DK1957073T3 (en) | PHARMACEUTICAL | |
EP1871347A4 (en) | PHARMACEUTICAL PREPARATION | |
DK2120884T3 (en) | Pharmaceutical composition | |
PT2209464E (en) | ANTIMALARIC PHARMACEUTICAL COMPOSITION | |
DK2966175T3 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING CORTEXOLON-17-ALPHA-PROPIONATE | |
EP1937255A4 (en) | PHARMACEUTICAL COMPOSITION |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20081006 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20100816 |
|
17Q | First examination report despatched |
Effective date: 20120301 |
|
DAX | Request for extension of the european patent (deleted) | ||
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 47/22 20060101ALI20121031BHEP Ipc: A61P 31/10 20060101ALI20121031BHEP Ipc: A61K 47/18 20060101ALI20121031BHEP Ipc: A61P 17/00 20060101ALI20121031BHEP Ipc: A61K 47/14 20060101ALI20121031BHEP Ipc: A61K 9/00 20060101ALI20121031BHEP Ipc: C07D 409/06 20060101ALI20121031BHEP Ipc: A61K 9/08 20060101ALI20121031BHEP Ipc: A61K 31/4178 20060101AFI20121031BHEP |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 606806 Country of ref document: AT Kind code of ref document: T Effective date: 20130515 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602006035753 Country of ref document: DE Effective date: 20130606 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: KELLER AND PARTNER PATENTANWAELTE AG, CH |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2421613 Country of ref document: ES Kind code of ref document: T3 Effective date: 20130904 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130417 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130817 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130718 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130819 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130417 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130417 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130717 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130417 |
|
REG | Reference to a national code |
Ref country code: PL Ref legal event code: T3 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130417 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130417 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130417 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130417 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130417 |
|
REG | Reference to a national code |
Ref country code: HU Ref legal event code: AG4A |
|
26N | No opposition filed |
Effective date: 20140120 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602006035753 Country of ref document: DE Effective date: 20140120 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130417 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PCAR Free format text: NEW ADDRESS: EIGERSTRASSE 2 POSTFACH, 3000 BERN 14 (CH) |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20130417 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 10 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 11 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 12 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 13 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PFA Owner name: NIHON NOHYAKU CO., LTD., JP Free format text: FORMER OWNER: NIHON NOHYAKU CO., LTD., JP |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: PL Payment date: 20240925 Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20241023 Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 20241022 Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: HU Payment date: 20241024 Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20241022 Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20241022 Year of fee payment: 19 Ref country code: FI Payment date: 20241022 Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20241024 Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20241024 Year of fee payment: 19 Ref country code: AT Payment date: 20241021 Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IE Payment date: 20241018 Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20241031 Year of fee payment: 19 Ref country code: ES Payment date: 20241118 Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20241023 Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20241101 Year of fee payment: 19 |